Evidence map›Paper›PMID 36542448›Full record

ArticleAnalytical methods : advancing methods and applications2023

Detrimental impact of aqueous mobile phases on 18F-labelled radiopharmaceutical analysis

Travis S Laferriere-Holloway, Alejandra Rios, R Michael van Dam

Abstract read
In one paragraph

Article in Analytical methods : advancing methods and applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Travis S Laferriere-HollowayDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA. mvandam@mednet.ucla.edu.ORCID 0000-0002-4533-4851
Alejandra RiosPhysics and Biology in Medicine Interdepartmental Graduate Program, UCLA, Los Angeles, CA, USA.
R Michael van DamDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA. mvandam@mednet.ucla.edu.ORCID 0000-0003-2316-0173

Funding

MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
Research Training in Biomedical PhysicsT32EB002101 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Michael F McNitt-Gray · 2003 to 2026
$5.3M
Accelerating the discovery and development of neurotracers via high-throughput radiochemistryR01EB032264 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHATZIIOANNOU, ARION XENOFON, VAN DAM, ROBERT MICHAEL · 2022 to 2025
$2.7M
Optimization and validation of integrated microscale technologies for low-cost, automated production of PET molecular imaging tracers for cancer researchR33CA240201 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2019 to 2021
$1.1M
High-throughput radiochemistry platform for accelerated discovery and development of novel PET imaging agents for cancerR21CA212718 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2017 to 2018
$616k
Novel microscale purification methods for complete microfluidic production of high molar activity PET radiotracersR21EB024243 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2019 to 2020
$429k
Radio-UPLC-MS for high-throughput analysis of short-lived radiolabeled compoundsS10OD026942 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2019 to 2019
$199k
NCI NIH HHS R21 CA212718NCI NIH HHS R33 CA240201NIBIB NIH HHS R01 EB032264NIBIB NIH HHS R21 EB024243NIBIB NIH HHS T32 EB002101NIGMS NIH HHS T34 GM008563NIH HHS S10 OD026942
6 · The paper itself

Abstract

The list of new positron-emission tomography (PET) tracers has rapidly grown in the past decade, following discoveries of new biological targets and therapeutic strategies, with several compounds garnering recent regulatory approval for clinical use. During the development of synthesis methods and production of new tracers for imaging, analytical methods for radio-high performance liquid chromatography (radio-HPLC) and radio-thin layer chromatography (radio-TLC) separations need to be developed to assess radiochemical compositions. Radio-TLC is often faster, simpler, and sometimes more accurate than radio-HPLC (as there is no underestimation of [

Indexed as

FluoridesRadiopharmaceuticalsChromatography, Thin LayerSilicon DioxideWaterFluoridesRadiopharmaceuticalsSilicon DioxideWater

Identifiers

PMID36542448
PMCPMC9891729

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.